Oral safusidenib begins trial as maintenance for high-grade glioma
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
News
Canada agency backs coverage of new ovarian cancer drug
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy Elahere (mirvetuximab soravtansine) under…
Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with…
Cero seeking more safety, dosing data on T-cell therapy for AML
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in…
November shines a spotlight on pancreatic cancer awareness
November is Pancreatic Cancer Awareness Month, and advocates nationwide are hosting events to unite the community and raise awareness about the condition. For this year’s…
Therapy wins rare pediatric disease designation for hard-to-treat glioma
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
Changes in tumor cells help make ovarian cancer treatment resistant
Specific genetic changes in small populations of tumor cells can help to make ovarian cancer resistant to treatment, a new study by U.S. researchers revealed.
Myeloma treatment HDP-101 put on FDA fast track
The U.S. Food and Drug Administration (FDA) has granted fast track designation to HDP-101 (pamlectabart tismanitin), a multiple myeloma therapy currently in early clinical…
FDA approves Revuforj for AML with NPM1 mutations
The U.S. Food and Drug Administration (FDA) has approved Syndax‘s oral therapy Revuforj (revumenib) as a treatment for certain people with acute myeloid leukemia…
Tango plans pivotal trial of vopimetostat for pancreatic cancer
Following new, positive data from a Phase 1/2 clinical study, Tango Therapeutics is planning to launch a pivotal trial to test its therapy candidate…
